compass route
LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that management will present at the following investor conferences Will participate in ,
Citi’s 18th Annual Biopharma Conference: Hosting Investor Meetups on September 7, 2023
HC Wainwright 25th Annual Global Investment Conference: Hosted Fireside Chat & Investor Meetings on Sep 11, 2023 at 3:30 PM
Morgan Stanley Annual Global Healthcare Conference: Will Host Investor Meetings on September 12, 2023
2023 Cantor Global Healthcare Conference: Fireside chat and investor meetings hosted on Sep 27, 2023 at 9:45 am
The live audio webcast of the fireside chat at the HC Wainwright and Cantor conferences will be accessible from the “Events” page of the “Investors” section of the Compass website. For each presentation, a replay of the webcast will be available for 30 days following such event. Please visit ir.compasspathways.com for more information.
about compass paths
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of people with mental health challenges that are not helped by current treatments. We are pioneers in the development of a new model of psilocybin therapy in which our proprietary formulation of synthetic psilocybin, COMP360, is administered along with psychosocial support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have initiated the Phase 3 clinical program of COMP360 psilocybin therapy at TRD, the largest randomized, controlled, double-blind psilocybin therapy clinical program to date. Previously, we completed a Phase 2B study with top line data showing a statistically significant (p < . 0.001) and a clinically relevant improvement was shown. We are also conducting Phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. Compass is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellness. www.compasspathways.com.
Availability of other information about compass paths
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com) and social media (LinkedIn), But not limited to these. investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information we post on these channels and websites may be considered material information. As a result, we encourage investors, the media and others interested in us to review the information we post on these channels, including the Investor Relations website, on a regular basis. This list of channels may be updated from time to time on our Investor Relations website and may include additional social media channels. The contents of our website or these channels, or any other website that can be accessed from our website or these channels, shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933.
inquiry
Media: Amy Lawrence, [email protected], +44 7813 777 919
Investor: Stephen Schultz, [email protected], +1 401 290 7324
Source
